This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
ResMed (RMD) reports a solid third-quarter top line, led by strong device sales growth through steady production and delivery of its cloud-connected flow generator devices to meet high market demand.
ResMed (RMD) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of 7.01% and 7.95%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Reasons Why You Should Retain ResMed (RMD) Stock For Now
by Zacks Equity Research
Investors are optimistic about ResMed's (RMD) Increased demand for its digital health solution.
EYE vs. RMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EYE vs. RMD: Which Stock Is the Better Value Option?
Reasons Why You Should Retain ResMed (RMD) Stock For Now
by Zacks Equity Research
Investors are optimistic about ResMed (RMD) owing to the increased demand for its sleep and respiratory care devices.
Top Research Reports for Chevron, Novo Nordisk & Amgen
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (CVX), Novo Nordisk A/S (NVO) and Amgen Inc. (AMGN).
ResMed's (RMD) Mask Sales Drive Growth, Margin Issue Lingers
by Zacks Equity Research
ResMed (RMD) continues to see robust demand for its market-leading mask portfolio despite being faced with challenges related to lower new patient setups from a competitor recall.
ESLOY vs. RMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
ESLOY vs. RMD: Which Stock Is the Better Value Option?
ResMed's (RMD) Q2 Earnings Beat Estimates, Margins Falls
by Zacks Equity Research
ResMed's (RMD) mask sales growth was strong across the globe, reflecting a post-COVID pandemic awareness about the importance and need for respiratory hygiene and respiratory health.
ResMed (RMD) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of 3.75% and 3.64%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Home Depot, Merck, Bank of America, Elevance Health and ResMed
by Zacks Equity Research
Home Depot, Merck, Bank of America, Elevance Health and ResMed are included in this Analyst Blog.
Top Analyst Reports for Home Depot, Merck & Bank of America
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), Merck & Co., Inc. (MRK) and Bank of America Corporation (BAC).
ResMed (RMD) Q1 Earnings In Line, Operating Margin Falls
by Zacks Equity Research
ResMed (RMD) continues to increase its access to semiconductor communications chips.
ResMed (RMD) Q1 Earnings Match Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of 0% and 0.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Landec (LNDC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Landec (LNDC) delivered earnings and revenue surprises of -166.67% and 1.89%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock?
ResMed (RMD) Gains on Product Uptake Even as Expenses Rise
by Zacks Equity Research
The continued uptake of ResMed's (RMD) core non-invasive ventilation and life support ventilation solutions for COPD and neuromuscular disease is encouraging.
Reasons Why You Should Retain ResMed (RMD) Stock For Now
by Zacks Equity Research
Investors are optimistic about ResMed's (RMD) better-than-expected results and robust device sales.
ResMed (RMD) Q4 Earnings Beat Estimates, Gross Margin Up
by Zacks Equity Research
ResMed (RMD) posts better-than-expected Q4 results with continued strength in sleep and respiratory care devices sales performance.
ResMed (RMD) Q4 Earnings Beat Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of 0.68% and 0.29%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ResMed Q4 Preview: Rebound Quarter Inbound?
by Derek Lewis
RMD has primarily exceeded the Zacks Consensus EPS Estimate. However, the company registered an 8% bottom-line miss in its latest quarter.
Nephros Inc. (NEPH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nephros Inc. (NEPH) delivered earnings and revenue surprises of 14.29% and 6.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
NuVasive (NUVA) Lags Q2 Earnings Estimates
by Zacks Equity Research
NuVasive (NUVA) delivered earnings and revenue surprises of -14.55% and 1.51%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
AngioDynamics (ANGO) Q4 Earnings in Line, Revenues Beat Mark
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth in Med Tech and Med Device businesses, as well as in its GBUs, in fourth-quarter fiscal 2022.